Discontinuation of potent antiretroviral therapy:: predictive value of and impact on CD4 cell counts and HIV RNA levels

被引:31
作者
Grant, LA
Silverberg, MJ
Palacio, H
Minkoff, H
Anastos, K
Young, MA
Nowicki, M
Kovacs, A
Cohen, M
Muñoz, A
机构
[1] Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA
[2] San Francisco Dept Publ Hlth, San Francisco, CA USA
[3] Maimonides Hosp, Brooklyn, NY 11219 USA
[4] SUNY Hlth Sci Ctr, Brooklyn, NY 11203 USA
[5] Montefiore Med Ctr, Bronx, NY 10467 USA
[6] Georgetown Univ, Med Ctr, Washington, DC 20007 USA
[7] Univ So Calif, Sch Med, Los Angeles Cty & Univ So Calif Med Ctr, Div Pediat Infect Dis, Los Angeles, CA USA
[8] Univ So Calif, Sch Med, Los Angeles Cty & Univ So Calif Med Ctr, Comprehens Maternal Child HIV Management & Res Ctr, Los Angeles, CA USA
[9] Cook Cty Hosp, Chicago, IL 60612 USA
关键词
CD4 cell count; discontinuation; HIV; plasma HIV RNA; potent antiretroviral therapy;
D O I
10.1097/00002030-200111090-00005
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective To characterize predictors and consequences of discontinuing antiretroviral therapy (,ART) in terms of CD4 cell count, HIV RNA, and reported side-effects in a large cohort of HIV-infected women. Design Cohort study. Methods A total of 1058 HIV-infected women initiated potent ART before September 1999. For each 6 month period after October 1996 we determined the proportion of potent ART users who downshifted to non-potent ART and who discontinued all ART. We examined the role of CD4 cell count and HIV RNA with regard to ART discontinuation. Results Between October 1996 and September 1999, 1058 individuals contributed 3362 visits at which potent ART was reported in the previous 6 months. Overall rates of 6 month downshifting and discontinuation were 10.0% and 6.7%. The proportion of individuals discontinuing all ART increased from 2.9% in late 1996 to 9.1% in mid 1999 (P <0.001). Individuals with high HIV RNA levels were more likely to discontinue (P <0.05). Compared to those who continued on potent ART, individuals who discontinued experienced large declines (P <0.001) in CD4 cell counts and were more than three times more likely (P <0.001) to experience HIV RNA increases. However, over one-third of those discontinuing ART reported side-effects and this subset had smaller CD4 cell count declines as compared to discontinuers not reporting side-effects (P=0.147). Conclusions In a large cohort of HIV-infected women, an increasing proportion of potent ART users discontinued ART over 3 years. Higher HIV RNA levels predicted discontinuation. Immediate immunological/virological deleterious consequences were observed. Side-effects were the most common reason for discontinuation and CD4 cell count declines were larger among those who did not cite side-effects as the reason for discontinuation. (C) 2001 Lippincott Williams & Wilkins.
引用
收藏
页码:2101 / 2108
页数:8
相关论文
共 22 条
[1]   Selection by indication of potent antiretroviral therapy use in a large cohort of women infected with human immunodeficiency virus [J].
Ahdieh, L ;
Gange, SJ ;
Greenblatt, R ;
Minkoff, H ;
Anastos, K ;
Young, M ;
Nowicki, M ;
Kovacs, A ;
Cohen, M ;
Muñoz, A .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 2000, 152 (10) :923-933
[2]   The Women's Interagency HIV Study [J].
Barkan, SE ;
Melnick, SL ;
Preston-Martin, S ;
Weber, K ;
Kalish, LA ;
Miotti, P ;
Young, M ;
Greenblatt, R ;
Sacks, H ;
Feldman, J .
EPIDEMIOLOGY, 1998, 9 (02) :117-125
[3]  
Bassetti S, 1999, J ACQ IMMUN DEF SYND, V21, P114
[4]   Antiretroviral therapy in adults - Updated recommendations of the International AIDS Society-USA Panel [J].
Carpenter, CCJ ;
Cooper, DA ;
Fischl, MA ;
Gatell, JM ;
Gazzard, BG ;
Hammer, SM ;
Hirsch, MS ;
Jacobsen, DM ;
Katzenstein, DA ;
Montaner, JSG ;
Richman, DD ;
Saag, MS ;
Schechter, M ;
Schooley, RT ;
Vella, S ;
Yeni, PG ;
Volberding, PA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (03) :381-390
[5]  
*CTR DIS CONTR PRE, 2000, MMWR-MORBID MORTAL W, V47, pRR5
[6]   Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration [J].
Detels, R ;
Muñoz, A ;
McFarlane, G ;
Kingsley, LA ;
Margolick, JB ;
Giorgi, J ;
Scharager, LD ;
Phair, JP .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (17) :1497-1503
[7]  
FAUCI A, 2000, 13 INT AIDS C DURB J
[8]  
GANGE SJ, 2001, IN PRESS J EPIDEMIOL
[9]   Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy [J].
Gulick, RM ;
Mellors, JW ;
Havlir, D ;
Eron, JJ ;
Gonzalez, C ;
McMahon, D ;
Richman, DD ;
Valentine, FT ;
Jonas, L ;
Meibohm, A ;
Emini, EA ;
Chodakewitz, JA .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (11) :734-739
[10]   A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less [J].
Hammer, SM ;
Squires, KE ;
Hughes, MD ;
Grimes, JM ;
Demeter, LM ;
Currier, JS ;
Eron, JJ ;
Feinberg, JE ;
Balfour, HH ;
Dayton, LR ;
Chodakewitz, JA ;
Fischl, MA .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (11) :725-733